DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) saw a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 191,900 shares, a decrease of 8.4% from the January 15th total of 209,500 shares. Based on an average daily volume of 103,200 shares, the short-interest ratio is currently 1.9 days.
DiaMedica Therapeutics Stock Performance
Shares of DMAC traded down $0.10 during mid-day trading on Friday, hitting $6.51. The company's stock had a trading volume of 74,665 shares, compared to its average volume of 86,781. DiaMedica Therapeutics has a one year low of $2.14 and a one year high of $6.82. The firm has a market capitalization of $278.37 million, a PE ratio of -11.62 and a beta of 1.46. The stock's 50-day moving average is $5.74 and its two-hundred day moving average is $4.80.
Institutional Investors Weigh In On DiaMedica Therapeutics
Several hedge funds have recently modified their holdings of DMAC. Blue Trust Inc. bought a new stake in shares of DiaMedica Therapeutics in the third quarter valued at approximately $185,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of DiaMedica Therapeutics in the third quarter valued at $40,000. Geode Capital Management LLC raised its stake in shares of DiaMedica Therapeutics by 29.6% in the third quarter. Geode Capital Management LLC now owns 306,958 shares of the company's stock valued at $1,286,000 after purchasing an additional 70,070 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of DiaMedica Therapeutics in the fourth quarter valued at $81,000. Finally, Meridian Wealth Management LLC acquired a new position in shares of DiaMedica Therapeutics in the fourth quarter valued at $148,000. 10.12% of the stock is owned by institutional investors.
Analyst Ratings Changes
Separately, HC Wainwright reissued a "buy" rating and issued a $7.00 price target on shares of DiaMedica Therapeutics in a research note on Friday, November 15th.
View Our Latest Stock Analysis on DMAC
About DiaMedica Therapeutics
(
Get Free Report)
DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.
See Also
Before you consider DiaMedica Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DiaMedica Therapeutics wasn't on the list.
While DiaMedica Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
